The European Medicines Agency (EMA) is warning patients and healthcare professionals to beware of pre-filled pens falsely labelled as Ozempic, a diabetes medicine linked to weight loss. National authorities notified the EU regulator after the pens, which are labelled in German and appear to have originated from wholesalers in Austria and Germany, were found in several locations in the EU […]
Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up to 3 years in adults. The findings were released on Oct 2, 2023 from the Annual Meeting of The European Association for the Study of Diabetes (EASD). “Our long-term analysis of semaglutide […]
Novo Nordisk presented data showing that an investigational 2.0 mg dose of Ozempic (semaglutide) provided statistically significant and superior reductions in blood sugar (HbA1C) compared with Ozempic 1.0 mg. These data were the outcome of the SUSTAIN FORTE trial, a phase IIIb, 40-week, efficacy and safety trial comparing once-weekly semaglutide 2.0 mg vs Ozempic 1.0 mg as add-on to metformin […]
Recent Comments